Q-omics provides the consensus-scored NDST3 profile across patient tissues and cancer cell-line models. NDST3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, NDST3 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, NDST3 RNA expression shows 13,898 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KIRC, and TGCT as cancer lineages where NDST3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDST3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDST3 survival associations across molecular data types. NDST3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDST3 RNA expression–survival associations across cancer types. High NDST3 expression shows unfavorable associations in UCEC, OV and ACC, but favorable associations in SCLC, LAML and LGG. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for NDST3 RNA expression.
This table summarizes NDST3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NDST3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDST3 shows lower tumor expression in KIRC, KICH, KIRP, LIHC and CHOL and higher tumor expression in BRCA. The KIRC box plot shows higher NDST3 RNA expression in normal versus tumor tissue (log2 FC = −0.706, t-test p < 0.001).
This table shows molecular features associated with NDST3 in patient tissues and cancer cell lines. In patient samples, NDST3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NDST3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
